Fundraising Fox

Obsidiantx

Founded 2015 · 108 employees on LinkedIn · 3 known investors

Obsidian Therapeutics develops engineered TIL (tumor-infiltrating lymphocyte) cell therapies for patients with solid tumors, with a lead clinical program (amsoki-cel / OBX-115) treating metastatic melanoma and non-small cell lung cancer. It also licenses its cytoDRiVE platform technology through partnerships to discover novel therapies.

BiotechHealthtech

Founders & leadership

Obsidiantx was founded in 2015 by Peter Barrett and Tom Wandless.

PBPeter Barrett
Peter BarrettCo-founder & Board Member
TWTom Wandless
Tom WandlessScientific Founder
MJMadan Jagasia
Madan JagasiainChief Executive Officer
PHParameswaran Hari
Parameswaran HariinChief Medical Officer
JFJulie Feder
Julie FederinChief Financial Officer
DADana Alexander
Dana AlexanderinChief Technical Officer
JPJennifer Peterson
Jennifer PetersoninChief People Officer

Investors · 3

Atlas VentureCambridge · $500K – $1M
TCG CrossoverPalo Alto
Vertex Ventures HCSingapore · $500K – $10M

Frequently asked questions

What does Obsidiantx do?
Obsidian Therapeutics develops engineered TIL (tumor-infiltrating lymphocyte) cell therapies for patients with solid tumors, with a lead clinical program (amsoki-cel / OBX-115) treating metastatic melanoma and non-small cell lung cancer. It also licenses its cytoDRiVE platform technology through partnerships to discover novel therapies.
Who founded Obsidiantx?
Obsidiantx was founded by Peter Barrett, Tom Wandless in 2015.
Who are Obsidiantx's investors?
Obsidiantx's investors include Atlas Venture, TCG Crossover, Vertex Ventures HC.